{"id":"perfluorohexyloctane","rwe":[],"_fda":{"id":"4cb37a53-376f-ef57-e063-6294a90a5bf8","set_id":"6b283c02-7df4-4c00-951b-555cddffe77c","openfda":{"nui":["N0000194071","N0000194072"],"upc":["0324208377055"],"unii":["7VYX4ELWQM"],"route":["OPHTHALMIC"],"rxcui":["2637551","2637556"],"spl_id":["4cb37a53-376f-ef57-e063-6294a90a5bf8"],"brand_name":["MIEBO"],"spl_set_id":["6b283c02-7df4-4c00-951b-555cddffe77c"],"package_ndc":["24208-377-05","24208-377-01","24208-377-06"],"product_ndc":["24208-377"],"generic_name":["PERFLUOROHEXYLOCTANE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PERFLUOROHEXYLOCTANE"],"pharm_class_epc":["Semifluorinated Alkane [EPC]"],"manufacturer_name":["Bausch & Lomb Incorporated"],"application_number":["NDA216675"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well controlled studies with MIEBO in pregnant women. In animal reproduction studies with oral administration of perfluorohexyloctane during the period of organogenesis, no adverse maternal or developmental effects were observed in rats at doses up to 162 times the recommended human ophthalmic dose (RHOD) ( see Data ). Maternal toxicity, miscarriages and reduced fetal weights were observed in rabbits at all doses tested, with the lowest dose as 41 times the RHOD. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Data Animal Data An embryofetal study was conducted in pregnant rabbits administered perfluorohexyloctane by oral gavage on gestation days 6 to 19, to target the period of organogenesis. Perfluorohexyloctane produced maternal toxicity, characterized by reduced body weight gain and food consumption, and miscarriages at all doses tested, with the lowest dose as ≥ 250 mg/kg/day (41 times the RHOD based on body surface area). Reduced fetal weights were also observed at ≥ 250 mg/kg/day but no fetal mortality or malformations. A no observed adverse effect level (NOAEL) for maternal toxicity was not established in rabbits. An embryofetal study was conducted in pregnant rats administered perfluorohexyloctane by oral gavage on gestation days 6 to 17, to target the period of organogenesis. There was no evidence of embryofetal toxicity or teratogenicity at doses up to 2,000 mg/kg/day (162 times the RHOD)."],"description":["11 DESCRIPTION MIEBO ® (perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless liquid containing 100% perfluorohexyloctane, for topical ophthalmic use. The active ingredient is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane and is a semifluorinated alkane. It has a molecular formula of C 14 H 17 F 13 and a molecular weight of 432.26 g/mol. The chemical structure is: Perfluorohexyloctane is practically immiscible with water. It is miscible with ethanol and most organic solvents. Each multiple-dose bottle contains 3 mL of perfluorohexyloctane, 1.338 g/mL as a clear and colorless liquid. A structure of a chemical formula AI-generated content may be incorrect."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING MIEBO ® (perfluorohexyloctane ophthalmic solution) is supplied as a sterile, clear and colorless liquid in multiple-dose 5 mL polypropylene bottles with dropper tips and screw caps, packaged in a carton - NDC 24208-377-05. Storage Store MIEBO at 15ºC to 25ºC (59ºF to 77ºF). After opening, MIEBO can be used until the expiration date on the bottle."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of MIEBO in pediatric patients below the age of 18 years have not been established."],"effective_time":"20260310","clinical_studies":["14 CLINICAL STUDIES In two randomized, multicenter, double-masked, saline-controlled trials (GOBI and MOJAVE), a total of 1,217 patients with a history of DED and clinical signs of meibomian gland dysfunction were randomized to MIEBO or saline 0.6% (1:1 ratio) to evaluate safety and efficacy after receiving MIEBO four times daily (QID) for 57 days.The mean age of the 614 patients who received MIEBO was 57 years (range, 19-87 years). The majority of patients were female (76%). Effects on Signs of Dry Eye Disease Total corneal fluorescein staining (tCFS) was recorded at each study visit using a standardized grading system of 0-3 for each of the five areas on the cornea (inferior, superior, central, nasal, and temporal), totaling a maximum tCFS score for each eye of 15. The average baseline tCFS was approximately 6.7 in GOBI and 7.0 in MOJAVE. At Days 15 and 57, a statistically significant reduction in tCFS favoring MIEBO was observed in both studies (Figure 1). Effects on Symptoms of Dry Eye Disease Eye dryness score was rated by patients using a visual analogue scale (VAS) (0=no discomfort, 100=maximal discomfort) at each study visit. The baseline VAS eye dryness average score was approximately 67 in GOBI and 65 in MOJAVE. At Days 15 and 57, a statistically significant reduction in VAS eye dryness score favoring MIEBO was observed in both studies (Figure 2). Table Description automatically generated Table Description automatically generated"],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of perfluorohexyloctane following topical ocular administration of MIEBO has not been quantitatively characterized in humans. A single pharmacokinetic (PK) study was conducted that showed low systemic perfluorohexyloctane blood levels after topical ocular administration. Perfluorohexyloctane was not metabolized by human liver microsomes in vitro."],"adverse_reactions":["6 ADVERSE REACTIONS Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients with DED, 614 patients received at least one dose of MIEBO in two randomized controlled clinical trials across 68 sites in the United States. The most common ocular adverse reaction was blurred vision. Blurred vision and conjunctival redness were reported in 1-3% of individuals. In four premarketing studies (three open-label [n=127], one randomized [n=24 treated with at least one dose of perfluorohexyloctane]) the most common adverse reaction was hypersensitivity."],"contraindications":["4 CONTRAINDICATIONS Hypersensitivity. ( 4.1 ) 4.1 Hypersensitivity MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane [see Adverse Reactions ( 6.1 )] ."],"mechanism_of_action":["12.1 Mechanism of Action Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known."],"recent_major_changes":["Contraindications, Hypersensitivity ( 4.1 ) 10/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known. 12.3 Pharmacokinetics The pharmacokinetics of perfluorohexyloctane following topical ocular administration of MIEBO has not been quantitatively characterized in humans. A single pharmacokinetic (PK) study was conducted that showed low systemic perfluorohexyloctane blood levels after topical ocular administration. Perfluorohexyloctane was not metabolized by human liver microsomes in vitro."],"indications_and_usage":["1 INDICATIONS AND USAGE MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS 5.1 Use with Contact Lenses MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of perfluorohexyloctane. Perfluorohexyloctane was not mutagenic or clastogenic in a standard battery of genotoxicity tests, including a bacterial mutagenicity assay (Ames assay), an in vitro chromosome aberration assay using human peripheral lymphocytes, and an in vivo bone marrow micronucleus assay in rats."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Use with Contact Lenses Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO. Administration Instructions Advise patients to instill one drop of MIEBO four times daily into each eye as depicted in the Administration Instructions [see Dosage and Administration ( 2.2 )] . Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Patented. See https://patents.bausch.com for US patent information. MIEBO is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2025 Bausch & Lomb Incorporated or its affiliates 9805301"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Instill one drop of MIEBO four times daily into each eye. ( 2.1 ) 2.1 Recommended Dosage Instill one drop of MIEBO four times daily into affected eye(s). Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO. 2.2 Administration Instructions Step 1. Remove the cap from eye drop bottle. Step 2. Holding the bottle upright, gently squeeze the bottle. Step 3. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle). Step 4. Keeping the bottle upside down, place the bottle above your eye and squeeze it again to release a drop into your eye. Repeat steps 1 - 4 for the second affected eye. Step 2. Step 3. Step 4."],"spl_product_data_elements":["MIEBO Perfluorohexyloctane PERFLUOROHEXYLOCTANE PERFLUOROHEXYLOCTANE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS MIEBO (perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless ophthalmic solution containing 100% perfluorohexyloctane. Ophthalmic solution: 100% perfluorohexyloctane. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well controlled studies with MIEBO in pregnant women. In animal reproduction studies with oral administration of perfluorohexyloctane during the period of organogenesis, no adverse maternal or developmental effects were observed in rats at doses up to 162 times the recommended human ophthalmic dose (RHOD) ( see Data ). Maternal toxicity, miscarriages and reduced fetal weights were observed in rabbits at all doses tested, with the lowest dose as 41 times the RHOD. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Data Animal Data An embryofetal study was conducted in pregnant rabbits administered perfluorohexyloctane by oral gavage on gestation days 6 to 19, to target the period of organogenesis. Perfluorohexyloctane produced maternal toxicity, characterized by reduced body weight gain and food consumption, and miscarriages at all doses tested, with the lowest dose as ≥ 250 mg/kg/day (41 times the RHOD based on body surface area). Reduced fetal weights were also observed at ≥ 250 mg/kg/day but no fetal mortality or malformations. A no observed adverse effect level (NOAEL) for maternal toxicity was not established in rabbits. An embryofetal study was conducted in pregnant rats administered perfluorohexyloctane by oral gavage on gestation days 6 to 17, to target the period of organogenesis. There was no evidence of embryofetal toxicity or teratogenicity at doses up to 2,000 mg/kg/day (162 times the RHOD). 8.2 Lactation There are no data on the presence of perfluorohexyloctane in human milk, the effects on the breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of MIEBO to an infant during lactation; however, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MIEBO. 8.4 Pediatric Use The safety and effectiveness of MIEBO in pediatric patients below the age of 18 years have not been established. 8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-377-05 Miebo® (perfluorohexyloctane ophthalmic solution) For Topical Ophthalmic Use Multiple-dose container Sterile Rx only 3 mL 9805201 SP63005 carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of perfluorohexyloctane. Perfluorohexyloctane was not mutagenic or clastogenic in a standard battery of genotoxicity tests, including a bacterial mutagenicity assay (Ames assay), an in vitro chromosome aberration assay using human peripheral lymphocytes, and an in vivo bone marrow micronucleus assay in rats."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Ophthalmic","category":"route"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"},{"label":"Dry eye disease","category":"indication"},{"label":"Bausch And Lomb Inc","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"195 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"178 reports"},{"date":"","signal":"EYE IRRITATION","source":"FDA FAERS","actionTaken":"167 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION","source":"FDA FAERS","actionTaken":"164 reports"},{"date":"","signal":"PRODUCT DELIVERY MECHANISM ISSUE","source":"FDA FAERS","actionTaken":"140 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"130 reports"},{"date":"","signal":"OCULAR HYPERAEMIA","source":"FDA FAERS","actionTaken":"108 reports"},{"date":"","signal":"CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR","source":"FDA FAERS","actionTaken":"106 reports"},{"date":"","signal":"PRODUCT USE COMPLAINT","source":"FDA FAERS","actionTaken":"102 reports"},{"date":"","signal":"PRODUCT COMPLAINT","source":"FDA FAERS","actionTaken":"93 reports"}],"commonSideEffects":[{"effect":"blurred vision","drugRate":"less than 4%","_validated":true,"placeboRate":""}],"contraindications":["MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane."],"specialPopulations":{"Lactation":"There are no data on the presence of perfluorohexyloctane in human milk, the effects on the breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes clear determination of the risk of MIEBO to an infant during lactation; however, the developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for MIEBO.","Pregnancy":"There are no adequate and well controlled studies with MIEBO in pregnant women. In animal reproduction studies with oral administration of perfluorohexyloctane during the period of organogenesis, no adverse maternal or developmental effects were observed in rats at doses up to 162 times the recommended human ophthalmic dose (RHOD). Maternal toxicity, miscarriages and reduced fetal weights were observed in rabbits at all doses tested, with the lowest dose as 41 times the RHOD. All pregnancies have risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.","Geriatric use":"No overall differences in safety and effectiveness have been observed between elderly and younger patients.","Paediatric use":"The safety and effectiveness of MIEBO in pediatric patients below the age of 18 years have not been established."}},"trials":[],"aliases":[],"company":"Bausch Health","patents":[{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Oct 1, 2035","useCode":"U-1900","territory":"US","drugProduct":false,"patentNumber":"10576154","drugSubstance":false},{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Jun 21, 2037","useCode":"U-1900","territory":"US","drugProduct":false,"patentNumber":"10507132","drugSubstance":false},{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2033","useCode":"U-1900","territory":"US","drugProduct":false,"patentNumber":"10449164","drugSubstance":false},{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2033","useCode":"U-1900","territory":"US","drugProduct":false,"patentNumber":"10369117","drugSubstance":false},{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2033","useCode":"U-1900","territory":"US","drugProduct":false,"patentNumber":"10058615","drugSubstance":false},{"applNo":"N216675","source":"FDA Orange Book","status":"Active","expires":"Sep 29, 2036","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11357738","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PERFLUOROHEXYLOCTANE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:11:54.995403+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:11:54.995295+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:12:22.161241+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:00.388386+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:11:53.657946+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PERFLUOROHEXYLOCTANE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:00.736950+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:53.138253+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:53.138281+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:12:16.392298+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:53.138286+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:12:02.284181+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314588/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:01.450348+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinica","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:12:07.442927+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:12:10.590880+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA216675","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:11:53.138289+00:00"}},"allNames":"miebo","offLabel":[],"synonyms":["perfluorohexyloctane","perfluorhexyloctane","miebo","NOV03","F6H8"],"timeline":[{"date":"2023-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAUSCH AND LOMB INC to Bausch And Lomb Inc"},{"date":"2023-05-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bausch And Lomb Inc)"},{"date":"2028-05-18","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"}],"aiSummary":"Perflurohexyloctane (Miebo), marketed by Bausch Health, is a novel treatment for Dry Eye Disease that mimics natural eye oils to maintain moisture. Its key strength lies in its unique mechanism of action, which differentiates it from traditional treatments and positions it as a valuable option in the dry eye market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"2023-05-18","orphan":false,"company":"BAUSCH AND LOMB INC","regulator":"FDA"}],"brandName":"Miebo","ecosystem":[{"indication":"Dry eye disease","otherDrugs":[],"globalPrevalence":400000000}],"mechanism":{"modality":"Small Molecule","drugClass":"Semifluorinated Alkane [EPC]","explanation":"Perfluorohexyloctane, semifluorinated alkane, contains perfluorinated carbon atoms and hydrogenated carbon atoms. Perfluorohexyloctane forms monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.","oneSentence":"Miebo works by mimicking the natural oils in the eyes to help maintain moisture.","technicalDetail":"Miebo (Perfluorohexyloctane) is a synthetic perfluorocarbon that is thought to work by forming a thin film on the surface of the eye, helping to reduce evaporation of the tear film and maintain ocular surface health."},"commercial":{"launchDate":"2023","_launchSource":"DrugCentral (FDA 2023-05-18, BAUSCH AND LOMB INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5730","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PERFLUOROHEXYLOCTANE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PERFLUOROHEXYLOCTANE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:18:02.206607","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:12:22.161683+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"exclusivity":[{"code":"NCE","date":"May 18, 2028"}],"genericName":"perfluorohexyloctane","indications":{"approved":[{"id":"perfluorohexyloctane-dry-eye-disease","name":"Dry Eye Disease","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Miebo"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bausch And Lomb Inc","drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07243275","phase":"PHASE4","title":"SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-02-18","conditions":["Dry Eye Disease (DED)"],"enrollment":260,"completionDate":"2026-09-30"},{"nctId":"NCT07128628","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":["Dry Eye Disease"],"enrollment":423,"completionDate":"2026-11"},{"nctId":"NCT07457021","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Ophthalmology Center Affiliated to Xiamen University","startDate":"2026-03-01","conditions":["Dry Eye Disease"],"enrollment":2000,"completionDate":"2029-09-30"},{"nctId":"NCT07054606","phase":"PHASE4","title":"A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-07-02","conditions":["Dry Eye"],"enrollment":104,"completionDate":"2025-11-03"},{"nctId":"NCT07111013","phase":"PHASE3","title":"A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease","status":"WITHDRAWN","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-12","conditions":["Dry Eye Disease"],"enrollment":0,"completionDate":"2027-04"},{"nctId":"NCT06309953","phase":"PHASE4","title":"A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2024-02-28","conditions":["Dry Eye"],"enrollment":99,"completionDate":"2024-06-17"},{"nctId":"NCT05723770","phase":"PHASE4","title":"Effects of NOV03 on the Tear Film","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-08-14","conditions":["Dry Eye Disease (DED)"],"enrollment":33,"completionDate":"2023-12-23"},{"nctId":"NCT06346340","phase":"PHASE4","title":"A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2024-04-30","conditions":["Dry Eye"],"enrollment":97,"completionDate":"2025-02-24"},{"nctId":"NCT06671041","phase":"PHASE4","title":"Treating Lid Wiper Epitheliopathy","status":"COMPLETED","sponsor":"Southern College of Optometry","startDate":"2024-05-27","conditions":["Dry Eye","Visual Acuity"],"enrollment":52,"completionDate":"2024-08-30"},{"nctId":"NCT06565650","phase":"PHASE4","title":"A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2024-07-31","conditions":["Dry Eye"],"enrollment":216,"completionDate":"2025-11"},{"nctId":"NCT04139798","phase":"PHASE3","title":"Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-07-20","conditions":["Dry Eye Disease (DED)"],"enrollment":599,"completionDate":"2021-03-12"},{"nctId":"NCT04567329","phase":"PHASE3","title":"Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-11-18","conditions":["Dry Eye Disease"],"enrollment":620,"completionDate":"2021-08-30"},{"nctId":"NCT06176651","phase":"PHASE4","title":"Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers","status":"COMPLETED","sponsor":"Gordon Schanzlin New Vision","startDate":"2023-09-21","conditions":["Dry Eye","Dry Eye, Evaporative","Dry Eye Disease","Evaporative Dry Eye","Evaporative Dry Eye Disease","Kerato Conjunctivitis Sicca"],"enrollment":49,"completionDate":"2024-04-05"},{"nctId":"NCT04140227","phase":"PHASE3","title":"Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2020-09-24","conditions":["Dry Eye Disease (DED)"],"enrollment":256,"completionDate":"2022-01-05"},{"nctId":"NCT05288582","phase":"NA","title":"Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2022-03-27","conditions":["Dry Eye"],"enrollment":20,"completionDate":"2022-11-30"},{"nctId":"NCT03333057","phase":"PHASE2","title":"Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2018-01-03","conditions":["Dry Eye Disease (DED)"],"enrollment":336,"completionDate":"2018-07-27"},{"nctId":"NCT04521465","phase":"","title":"Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-11-09","conditions":["Evaporative Dry Eye Disease"],"enrollment":36,"completionDate":"2021-02-17"},{"nctId":"NCT03048526","phase":"NA","title":"Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-12-15","conditions":["Dry Eye Disease"],"enrollment":48,"completionDate":"2017-04-18"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"OPHTHALMIC","productName":"MIEBO"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"367213","NDDF":"017820","UNII":"7VYX4ELWQM","VANDF":"4042329","INN_ID":"12751","RXNORM":"2637547","UMLSCUI":"C0766224","chemblId":"CHEMBL5314588","KEGG_DRUG":"D12604","PUBCHEM_CID":"10477896"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION","route":"OPHTHALMIC","company":"Bausch & Lomb Incorporated","brandName":"MIEBO","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Bausch And Lomb Inc","relationship":"Original Developer"}],"publicationCount":132,"therapeuticAreas":["Ophthalmology"],"_revenueScrapedAt":"2026-03-31 09:35:41.456578+00","biosimilarFilings":[],"originalDeveloper":"Bausch And Lomb Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Bausch And Lomb Inc","companyId":"bausch","modality":"Small molecule","firstApprovalDate":"2023","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":"NDA216675"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2023-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB INC","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:12:22.161683+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}